Paroxysmal Nocturnal Hemoglobinuria (PNH)

ASH 2023 Update - Aplastic Anemia and PNH

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Presenter(s)
David Dingli, M.D., Ph.D.
In this webinar, Dr. David Dingli presents the latest research presented the American Society of Hematology meeting on Aplastic Anemia and PNH. This is an advanced presentation.

Danicopan

VOYDEYA is a prescription medicine used along with ravulizumab or

Biosimilars

What is a Biosimilar?

A biosimilar is a type of biologic medication. The term “biosimilar” means that the medication is highly similar to the already approved brand name biologic (“originator” medication). Biosimilars are not generic versions of the original biologic.

Subscribe to Paroxysmal Nocturnal Hemoglobinuria (PNH)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.